Table 1.
Ranking of the first-line systemic treatments for advanced HCC according to their probability of being the best in OS and PFS
| Fifteen-month OS | Thirty-month OS | Six-month PFS | |||
|---|---|---|---|---|---|
| treatment | SUCRA | treatment | SUCRA | treatment | SUCRA |
| Sintilimab + IBI305 | 0.946 | Atezolizumab + bevacizumab | 0.883 | Pembrolizumab + lenvatinib | 0.926 |
| Atezolizumab + bevacizumab | 0.843 | Camrelizumab + apatinib | 0.865 | Lenvatinib | 0.858 |
| Camrelizumab + apatinib | 0.804 | Pembrolizumab + lenvatinib | 0.722 | Camrelizumab + apatinib | 0.786 |
| Pembrolizumab + lenvatinib | 0.586 | Durvalumab + tremelimumab | 0.626 | Sintilimab + IBI305 | 0.712 |
| Lenvatinib | 0.553 | Nivolumab | 0.506 | Atezolizumab + cabozantinib | 0.695 |
| Atezolizumab + cabozantinib | 0.467 | Lenvatinib | 0.466 | Atezolizumab + bevacizumab | 0.518 |
| Durvalumab + tremelimumab | 0.410 | Tislelizumab | 0.352 | Sorafenib | 0.347 |
| Nivolumab | 0.319 | Durvalumab | 0.342 | Durvalumab + tremelimumab | 0.324 |
| Durvalumab | 0.264 | Atezolizumab + cabozantinib | 0.120 | Nivolumab | 0.153 |
| Tislelizumab | 0.195 | Sorafenib | 0.114 | Durvalumab | 0.107 |
| Sorafenib | 0.111 | – | – | Tislelizumab | 0.070 |
SUCRA, Surface Under the Cumulative Ranking.